1,099,885 Shares in Hologic, Inc. (NASDAQ:HOLX) Purchased by Champlain Investment Partners LLC

Champlain Investment Partners LLC purchased a new stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 1,099,885 shares of the medical equipment provider's stock, valued at approximately $79,291,000. Champlain Investment Partners LLC owned about 0.49% of Hologic as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of the business. Stifel Financial Corp boosted its stake in shares of Hologic by 115.8% in the 3rd quarter. Stifel Financial Corp now owns 20,354 shares of the medical equipment provider's stock valued at $1,658,000 after purchasing an additional 10,924 shares in the last quarter. Barclays PLC grew its stake in shares of Hologic by 47.6% during the third quarter. Barclays PLC now owns 718,231 shares of the medical equipment provider's stock worth $58,507,000 after buying an additional 231,578 shares during the last quarter. Sanctuary Advisors LLC lifted its stake in shares of Hologic by 4.2% in the 3rd quarter. Sanctuary Advisors LLC now owns 16,613 shares of the medical equipment provider's stock valued at $1,312,000 after acquiring an additional 667 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new stake in Hologic during the 3rd quarter worth $93,000. Finally, Tidal Investments LLC raised its position in Hologic by 60.1% in the third quarter. Tidal Investments LLC now owns 15,351 shares of the medical equipment provider's stock valued at $1,250,000 after purchasing an additional 5,764 shares during the last quarter. Institutional investors and hedge funds own 94.73% of the company's stock.

Hologic Stock Up 2.0 %

HOLX traded up $1.12 during trading on Tuesday, hitting $58.06. 369,688 shares of the company's stock were exchanged, compared to its average volume of 1,947,910. Hologic, Inc. has a fifty-two week low of $55.89 and a fifty-two week high of $84.67. The stock has a market cap of $13.03 billion, a P/E ratio of 18.32, a PEG ratio of 2.14 and a beta of 0.82. The business's 50 day moving average is $61.45 and its two-hundred day moving average is $70.54. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. As a group, equities analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the company. Stephens reaffirmed an "overweight" rating and issued a $84.00 price objective on shares of Hologic in a research note on Thursday, February 6th. Evercore ISI dropped their price target on shares of Hologic from $76.00 to $73.00 and set an "in-line" rating for the company in a research note on Thursday, February 6th. Raymond James reissued an "outperform" rating and issued a $90.00 price objective (down previously from $95.00) on shares of Hologic in a research note on Thursday, February 6th. Argus downgraded Hologic from a "buy" rating to a "hold" rating in a report on Monday, March 3rd. Finally, William Blair reissued an "outperform" rating on shares of Hologic in a research note on Thursday, February 6th. Eleven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, Hologic currently has an average rating of "Hold" and a consensus target price of $84.62.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.